Entrectinib, a novel treatment for TRK fusions, shows early promise against a range of cancer types
Entrectinib, a novel treatment for TRK fusions, shows early promise against a range of cancer types
First outcome results from MINDACT breast cancer clinical trial
Genetics may influence risk for breast cancer after chest radiotherapy to treat childhood cancer
A presurgery combination therapy may improve outcomes for women with Her2-positive breast cancer
5 year survival rates for nivolumab-treated metastatic melanoma patients much higher than historical rates
CD4 T-cell immunotherapy targeting MAGE-A3 is safe, and shows early clinical responses
New investigational targeted therapeutic, entrectinib, shows early promise
Paediatric and adult high grade gliomas: A tale of a histone tail
Galectins in tumour immunity
Treatment of relapsed myeloma with novel targeted and immune therapies
Targeting T regs in tumours
Multiplex IHC as biomarkers for cancer immunotherapy